MindBio Pursues Dual Listing Amidst Ongoing Phase 2B Trials and Positive Data

MindBio Therapeutics, a biopharmaceutical company at the forefront of developing innovative treatments for mental health conditions, has recently reported positive results from its Phase 1 and Phase 2a clinical trials. The company's lead drug candidate, MB22001, a proprietary form of Lysergic Acid Diethylamide (LSD) intended for safe at-home microdosing, has shown significant promise in treating depression.

In February 2024, MindBio concluded its Phase 2a trial with MB22001 on patients suffering from Major Depressive Disorder. The open-label trial demonstrated a remarkable 60% reduction in depressive symptoms, with over half of the participants achieving remission by week 8. The trial also recorded a significant mean decrease of 14.1 points in the MADRS score, a standardized scale for measuring the severity of depression.

Previous trials with MB22001 have not only improved sleep duration and quality but have also led to substantial increases in subjective well-being, with participants reporting enhanced feelings of happiness, social connectivity, energy, creativity, and wellness, alongside reduced anger and irritability.

Currently, MindBio is conducting two pivotal Phase 2B clinical trials, with dosing already initiated. An additional Phase 2B trial focusing on women's health has also received approval. These trials are groundbreaking, as they are the first in the world to allow the at-home use of MB22001.

The company plans to publish further results from the Phase 1 and 2A trials later in 2024 and anticipates announcing the outcomes of the Phase 2B trials in 2025. Preparations for Phase 3 Clinical Trials are underway, with discussions being held with Clinical Research Organizations (CROs) for a potential start in 2025.

MindBio stands out as one of the few public companies to have advanced to Phase 2 and Phase 3 clinical trials in the field of psychedelic medicines. As the most advanced clinical trial stage biopharma company listed on the Canadian Securities Exchange, MindBio is uniquely positioned for a potential dual listing on a senior exchange, discussions for which are currently underway with investment groups in Canada, the United States, and Australia.

The company's commitment to research and development is evident in its multi-disciplinary approach to creating novel treatments, including digital technologies and interventions, aimed at addressing debilitating mental health conditions such as depression and anxiety. With a focus on microdosing psychedelic medicines, MindBio is not only advancing its drug protocols through clinical trials but also setting new standards in the treatment of mental health.

MindBio Therapeutics is dedicated to pioneering new frontiers in mental health treatment, and its progress thus far is a testament to its innovative spirit and scientific rigor. As the company moves forward with its clinical trials and exploration of new treatment modalities, it continues to be a significant player in the field of psychedelic medicine and mental health care.